Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 431 | 10q22.2 | PLAU | plasminogen activator, urokinase | |
Mouse | - | 433 | 14 11.53 cM | Plau | plasminogen activator, urokinase | |
Rat | - | 432 | 15p16 | Plau | plasminogen activator, urokinase |
Previous and Unofficial Names |
uPA | UPAM | U-plasminogen activator | URK | plasminogen activator |
Database Links | |
Specialist databases | |
MEROPS | S01.231 (Hs) |
Other databases | |
Alphafold | P00749 (Hs), P06869 (Mm), P29598 (Rn) |
BRENDA | 3.4.21.73 |
ChEMBL Target | CHEMBL3286 (Hs), CHEMBL1075311 (Mm), CHEMBL1075245 (Rn) |
DrugBank Target | P00749 (Hs) |
Ensembl Gene | ENSG00000122861 (Hs), ENSMUSG00000021822 (Mm), ENSRNOG00000010516 (Rn) |
Entrez Gene | 5328 (Hs), 18792 (Mm), 25619 (Rn) |
Human Protein Atlas | ENSG00000122861 (Hs) |
KEGG Enzyme | 3.4.21.73 |
KEGG Gene | hsa:5328 (Hs), mmu:18792 (Mm), rno:25619 (Rn) |
OMIM | 191840 (Hs) |
Orphanet | ORPHA223447 (Hs) |
Pharos | P00749 (Hs) |
RefSeq Nucleotide | NM_002658 (Hs), NM_001145031 (Hs), NM_008873 (Mm), NM_013085 (Rn) |
RefSeq Protein | NP_002649 (Hs), NP_001138503 (Hs), NP_032899 (Mm), NP_037217 (Rn) |
SynPHARM | 78434 (in complex with compound 4 [PMID: 18163548]) |
UniProtKB | P00749 (Hs), P06869 (Mm), P29598 (Rn) |
Wikipedia | PLAU (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immuno Process Associations | ||
|
||
|
||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||||
|
1. Barber CG, Dickinson RP, Fish PV. (2004) Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett, 14 (12): 3227-30. [PMID:15149680]
2. Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, Fildes K, Cheung CY, Cook SM, Johnson DC et al.. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. J Med Chem, 61 (18): 8299-8320. [PMID:30130401]
3. Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinković M, Wallis NG. (2008) Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem, 51 (2): 183-6. [PMID:18163548]
4. Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA. (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost, 93 (4): 779-86. [PMID:15841327]
5. Stürzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikström P. (1999) 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett, 9 (21): 3147-52. [PMID:10560742]
S1: Chymotrypsin: plasminogen activator, urokinase. Last modified on 05/02/2024. Accessed on 11/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393.